Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Ashish Juvekar"'
Autor:
Gerburg M. Wulf, Lewis C. Cantley, John M. Asara, Ralph Scully, José Baselga, Pier Paolo Pandolfi, Caterina Nardella, Costas A. Lyssiotis, Katherine Spencer, Antonella Papa, Anbazhagan Rajendran, Judith Balmañà, Yasir H. Ibrahim, Elaine P. Lunsford, Hai Hu, Laura N. Burga, Ashish Juvekar
PDF file - 319K, Target inhibition after treatments with NVP-BKM120 in vivo. Tumor-bearing MMTV-CreBRCA1f/fp53+/- mice were biopsied before treatment, and tumor tissues harvested within 3 hours after the last treatment. Tissues were fixed and process
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1398ed6f3fdcab01db488d89fe89b601
https://doi.org/10.1158/2159-8290.22529226.v1
https://doi.org/10.1158/2159-8290.22529226.v1
Autor:
Gerburg M. Wulf, Lewis C. Cantley, John M. Asara, Ralph Scully, José Baselga, Pier Paolo Pandolfi, Caterina Nardella, Costas A. Lyssiotis, Katherine Spencer, Antonella Papa, Anbazhagan Rajendran, Judith Balmañà, Yasir H. Ibrahim, Elaine P. Lunsford, Hai Hu, Laura N. Burga, Ashish Juvekar
PDF file - 526K, FDG-uptake and CT-PET scanning of mice before and after 2 weeks of treatment with NVP-BKM120. Tumor-bearing female MMTV-CreBRCA1f/fp53+/- mice were imaged with PET-CT scans before and after treatments with NVP-BKM120 at 50 mg/kg/day.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::042b657504fec7d182fdbab88931d869
https://doi.org/10.1158/2159-8290.22529223.v1
https://doi.org/10.1158/2159-8290.22529223.v1
Autor:
Gerburg M. Wulf, Lewis C. Cantley, John M. Asara, Ralph Scully, José Baselga, Pier Paolo Pandolfi, Caterina Nardella, Costas A. Lyssiotis, Katherine Spencer, Antonella Papa, Anbazhagan Rajendran, Judith Balmañà, Yasir H. Ibrahim, Elaine P. Lunsford, Hai Hu, Laura N. Burga, Ashish Juvekar
PDF file - 169K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7aed6bc2eb311b19cfcc4c53528de3a
https://doi.org/10.1158/2159-8290.22529208
https://doi.org/10.1158/2159-8290.22529208
Autor:
Gerburg M. Wulf, Lewis C. Cantley, John M. Asara, Ralph Scully, José Baselga, Pier Paolo Pandolfi, Caterina Nardella, Costas A. Lyssiotis, Katherine Spencer, Antonella Papa, Anbazhagan Rajendran, Judith Balmañà, Yasir H. Ibrahim, Elaine P. Lunsford, Hai Hu, Laura N. Burga, Ashish Juvekar
PDF file - 71K, In vitro responses of BRCA1-mutant breast cancer cell lines to treatments with NVP-BKM120 (1 muM), Olaparib (10 muM) or their combination. Cells were seeded in quadruplicate in 96-well plates and treated for 7 days as indicated. A. HC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::141c3c8bd8873269a3d3412d1985e33e
https://doi.org/10.1158/2159-8290.22529217.v1
https://doi.org/10.1158/2159-8290.22529217.v1
Autor:
Gerburg M. Wulf, Lewis C. Cantley, John M. Asara, Ralph Scully, José Baselga, Pier Paolo Pandolfi, Caterina Nardella, Costas A. Lyssiotis, Katherine Spencer, Antonella Papa, Anbazhagan Rajendran, Judith Balmañà, Yasir H. Ibrahim, Elaine P. Lunsford, Hai Hu, Laura N. Burga, Ashish Juvekar
PDF file - 137K, Effects of the combination of NVP-BKM120 and Olaparib (left pair, treated with NVP-BKM120 at 30 mg/kg/day and Olaparib at 50 mg/kg/day) and of Olaparib alone (right pair, 50 mg/kg/day). Mice were imaged before and after 3 daily treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::205fb694d1494a35784fc344dc911ec4
https://doi.org/10.1158/2159-8290.22529220
https://doi.org/10.1158/2159-8290.22529220
Autor:
Gerburg M. Wulf, Lewis C. Cantley, John M. Asara, Ralph Scully, José Baselga, Pier Paolo Pandolfi, Caterina Nardella, Costas A. Lyssiotis, Katherine Spencer, Antonella Papa, Anbazhagan Rajendran, Judith Balmañà, Yasir H. Ibrahim, Elaine P. Lunsford, Hai Hu, Laura N. Burga, Ashish Juvekar
PDF file - 159K, Erk phosphorylation after treatments with NVP-BKM120 in vivo. Tumor tissues were harvested from MMTV-CreBRCA1f/fp53+/- mice within 3 hours after the last treatment with NVP-BKM120. Tissues were fixed and processed for immunohistochem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aed73b3e47946d19e949944d065a9583
https://doi.org/10.1158/2159-8290.22529211
https://doi.org/10.1158/2159-8290.22529211
Autor:
Paul A. Smith, Michael C. Milone, Ahmad Naim, Taisheng Huang, Lisa Truong, Yan-ou Yang, Ashish Juvekar, John Leferovich, Selene Nunez-Cruz, Michael T. Peel, Roddy S. O'Connor, Eduardo Huarte
Huate et al supplemental figures.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4624955c469e3b89fb27b5ef4b3427fd
https://doi.org/10.1158/1078-0432.22476738.v1
https://doi.org/10.1158/1078-0432.22476738.v1
Autor:
Paul A. Smith, Michael C. Milone, Ahmad Naim, Taisheng Huang, Lisa Truong, Yan-ou Yang, Ashish Juvekar, John Leferovich, Selene Nunez-Cruz, Michael T. Peel, Roddy S. O'Connor, Eduardo Huarte
Purpose:T cells engineered to express a chimeric antigen receptor (CAR) are a promising cancer immunotherapy. Such targeted therapies have shown long-term relapse-free survival in patients with B-cell leukemia and lymphoma. However, cytokine release
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f96fd1054c302babc70a79452d8dfef
https://doi.org/10.1158/1078-0432.c.6529476.v1
https://doi.org/10.1158/1078-0432.c.6529476.v1
Autor:
Yue Zou, Srijita Dhar, Kirsten Gallagher, Andrew Buesking, Sarah Pawley, Ryan Holmes, Xiaowei Wu, Katarina Rohlfing, Min Wang, Joseph Rager, Tom Emm, Stefan Ruepp, Miles Cowart, Jing Ni, Jean Zhao, Bruce Ruggeri, Andrew Combs, Kris Vaddi, Sandy Geeganage, Ashish Juvekar, Sang Hyun Lee, Peggy Scherle
Publikováno v:
Cancer Research. 83:5973-5973
Cell cycle deregulation is a hallmark of cancer and the hyperactivation and overexpression of CDKs are often drivers of cancer pathogenesis. Cyclin-dependent kinase 4 and 6 (CDK4)/(CDK6) are critical mediators of cellular transition into S phase and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fe20e98999d400271cbbc5365025a3f
https://doi.org/10.1158/1538-7445.am2023-5973
https://doi.org/10.1158/1538-7445.am2023-5973
Autor:
Paul A. Smith, Yan-ou Yang, Ashish Juvekar, Roddy S. O’Connor, Michael Peel, Selene Nunez-Cruz, Ahmad Naim, Michael C. Milone, Eduardo Huarte, Taisheng Huang, Lisa Truong, John Leferovich
Publikováno v:
Clin Cancer Res
Purpose: T cells engineered to express a chimeric antigen receptor (CAR) are a promising cancer immunotherapy. Such targeted therapies have shown long-term relapse-free survival in patients with B-cell leukemia and lymphoma. However, cytokine release
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edaa14ed4e2b1c5fe82f477c16a47641
https://doi.org/10.1158/1078-0432.ccr-20-1739
https://doi.org/10.1158/1078-0432.ccr-20-1739